Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

Table 3 Univariate analysis of tumor and clinical risk factors for overall survival in the Yale University cohort

	Yale University cohort
Variable	No. of patients (%) (n = 651)	HR	95% CI	P*
Age at diagnosis	645 (99.1)	0.999	0.988-1.009	0.890
Unknown/missing	6 (0.9)
Menopausal status
Premenopausal	196 (30.1)	1.000		0.436
Postmenopausal	449 (69.0)	1.115	0.848-1.482
Unknown/missing	6 (0.9)
Tumor size (cm)
≤ 2	215 (33.0)	1.000		< 0.0001
2-5	283 (43.5)	1.682	1.254-2.258
≥ 5	101 (15.5)	2.911	2.074-4.086
Other	52 (8.0)
Nodal status
Negative for node metastasis	327 (50.2)	1.000		< 0.0001
Positive for node metastasis	320 (49.2)	2.286	1.795-2.910
Unknown/missing	4 (0.6)
Positive nodes	320 (49.2)	1.022	1.001-1.042	0.040
Total nodes	625 (96.0)	0.978	0.961-0.994	0.010
Unknown/missing	26 (4.0)
Nuclear grade
Small/uniform nuclei	113 (17.4)	1.000		0.0007
Intermediate nuclei	315 (48.4)	1.231	0.854-1.818
Large nuclei	170 (26.1)	1.594	1.192-2.123
Other	53 (8.1)
ER status
ER negative	289 (44.4)	1.000		0.0005
ER positive	326 (50.1)	0.766	0.598-0.981
Other	36 (5.5)
PR status
PR negative	294 (45.2)	1.000		< 0.0001
PR positive	302 (46.4)	0.675	0.524-0.871
Other	55 (8.4)
HER2 status
HER2 negative	495 (76.0)	1.000		0.153
HER2 positive	109 (16.7)	1.270	1.048-1.317
Other	47 (7.2)
MAP-tau expression
MAP-tau low expression	376 (57.8)	1.000		0.0042
MAP-tau high expression	104 (16.0)	0.691	0.489-0.974
Unknown/missing	171 (26.3)

* P is given for Cox univariate analysis, statistically significant P values (P < 0.05) are in bold, trending P values are in italics; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.